Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Shelly Krebs

Chief, B cell Immunology

Walter Reed Army Institute of Research

United States

Research Interests

Explore related searches

Recent Grants

Grant: Close

Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals

Open Date: 2021-04-13

Close Date: 2026-03-31

Articles (20)

Collaborators (4)

Julie L. Mitchell

Research Assistant Professor

Oregon Health & Science University

UNITED STATES

Xiaoying Yu

La Jolla Institute for Allergy and Immunology

UNITED STATES

Rafael Freitas de Oliveira Franca

Research Associate - Principal Investigator

Oswaldo Cruz Foundation

Gary Matyas

Chief, Adjuvants and Formulation

Walter Reed Army Institute of Research

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Shelly Krebs

Research Interests

Explore related searches

Recent Grants

Articles (20)

Collaborators (4)

Julie L. Mitchell

Xiaoying Yu

Rafael Freitas de Oliveira Franca

Gary Matyas

Make your next move.

Shelly Krebs

Research Interests

Explore related searches

Recent Grants

Articles (20)

CD4dimCD8bright T cells are inversely associated with neuro-inflammatory markers among people with HIV

Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain

Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding

Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques

Informing the Need for a SARS-CoV-2 Booster Based on the Immune Responses Among Young Healthy Adults to Variants Circulating in Late 2023

Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice

Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium

Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes

Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters

Distinct mucosal and systemic immunological characteristics in transgender women potentially relating to HIV acquisition

Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies

Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States

Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity

Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity

Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in <i>E. coli</i> Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants

Collaborators (4)

Julie L. Mitchell

Xiaoying Yu

Rafael Freitas de Oliveira Franca

Gary Matyas

Make your next move.